cardiometabolic
Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery
Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news
Spotlight On: What to Watch at AHA 2025 – Key Science and Trends
AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines
Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat
ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health
Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility
Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience
Chronic care startup Omada Health files to go public
Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech